- Joined
- May 8, 2012
- Messages
- 648
- Reaction score
- 437
The CMS thread from @DocEspana sparked some discussion surrounding chest pain disposition and how to incorporate high sensitivity troponin assays and clinical decision tools into that framework. I have encountered three different pathways at three different shops. Some of the cardiologists I've talked to don't really seem to know how to deal with the new troponin assays. Reading some of the discussion on the other thread, this seems to be an area of significant practice pattern variation. I have a some questions for y'all:
1. If you have high sensitivity troponin in your shop, what is your department approved pathway guiding chest pain disposition for patients with suspicion of ACS?
2. Do you follow the ACEP clinical practice guideline to a t (i.e. if HEART >3, the patient can never be "low risk"?)
3. What situations will you accept a single troponin as sufficient evidence that chest pain is low risk?
4. How easy is it to routinely admit non-low risk patients to the hospitalist for further eval in the absence of clear ECG abnormalities or "elevated" troponin? Assuming you don't have an observation unit to punt these folks into.
1. If you have high sensitivity troponin in your shop, what is your department approved pathway guiding chest pain disposition for patients with suspicion of ACS?
2. Do you follow the ACEP clinical practice guideline to a t (i.e. if HEART >3, the patient can never be "low risk"?)
3. What situations will you accept a single troponin as sufficient evidence that chest pain is low risk?
4. How easy is it to routinely admit non-low risk patients to the hospitalist for further eval in the absence of clear ECG abnormalities or "elevated" troponin? Assuming you don't have an observation unit to punt these folks into.